Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Friday, November 6, 2026

⚡ Executive Takeaway

The approval cycle does not read the tape. At 5:32 on Thursday evening, with the S&P closing its worst session of the year, the FDA posted an accelerated approval built on a 102 patient single arm study, and three hours later Johnson and Johnson claimed the first dual targeted therapy in head and neck cancer. The same split ran through the week: AstraZeneca is reportedly bidding ten billion dollars for Rhythm while public investors spent the day repricing AI capital spending, and BD committed nineteen billion dollars of US investment to buy tariff certainty while its sector sold off around it.

The marginal buyer of clinical data right now is a regulator or a strategic, not the tape. Hold one detail from Thursday: BD closed green on results day against a 4.4 percent market decline, and Viatris outperformed on a raised year. Operational certainty is the one thing this market still pays for on a bad day, and the companies selling it were the only ones clearing higher.

🧬 A New Target Class Lands in Head and Neck Cancer

The FDA granted accelerated approval to subcutaneous amivantamab for recurrent or metastatic head and neck cancer Thursday evening, on a 42% response rate in a single arm study. JNJ

📉 The Election Rally Lasted One Session

The S&P 500 fell 4.4% and the Nasdaq entered correction territory as the AI selloff resumed, and healthcare's midterm pop round tripped. XBI | SPY

Wire reports put the Dow's loss at roughly 1,800 points on the day. For this sector the story is the round trip: Amgen closed at $460.28, down 3.8% and below where it traded before Wednesday's print, which settles the grade on the week's first higher clearing beat as rally beta rather than a data premium. XBI fell 6.7% to 148.40. Illumina fell another 8.2% with no disclosure we could find, 12.7% over two sessions, and its October 29 report had raised guidance. Karyopharm fell 17.6% toward next week's delisting. The exceptions were the companies that reported: BD closed up 2.1% on results day and Viatris held to a 1.3% dip on a raised year. All closes are settled exchange prices; the percentages are our arithmetic.

💊 Reuters Advances the AstraZeneca Bid for Rhythm

Reuters put AstraZeneca's nonbinding offer for Rhythm at about $10 billion, as much as $134 per share including milestone payments, pursued through Alexion. RYTM | AZN

The construction matters. The Wall Street Journal's Wednesday report had the offer at $124 per share, made last month; Reuters, citing three people, has up to $134 including contingent milestones. The two figures are not reconciled, and neither company has commented. Jefferies' Michael Leuchten called the rare disease fit entirely sensible and said the March approval of Imcivree in acquired hypothalamic obesity materially changed what Rhythm is. The stock gave back 5.1% to $105.02 on the market's worst day of the year, still 21.5% above its pre report close, our arithmetic. Two checkpoints land fast: Rhythm expects its initial $250 million credit facility draw today, the behavior of a company planning to stay independent, and the final Phase 3 acquired hypothalamic obesity dataset reads at ObesityWeek, November 14 to 17.

🏭 Viatris Raised Its Year and Priced a Plant Problem

Viatris raised its 2026 guidance midpoints on every metric, expects Pacira to close this month, and put the Nashik suspension at about $100 million a quarter. VTRS

Third quarter revenues were $3.75 billion, flat, with adjusted earnings of $0.71 per share, up 6%. The new midpoints: revenue $14.8 billion, adjusted EPS $2.60, adjusted EBITDA $4.5 billion and free cash flow $2.3 billion excluding deal costs, all up from August. The Pacira acquisition is excluded from guidance and expected to close by the end of November at $36.50 per share, a $1.65 billion equity value.

The operational story is Nashik. The FDA classified the Indian oral solid dose plant Official Action Indicated, Viatris suspended manufacturing there voluntarily in October, and the bill is about $100 million of revenue in the third quarter and about the same again in the fourth, with production back in the first quarter of 2027. A diversified base absorbed a two hundred million dollar plant problem and still raised the year. New products contributed about $115 million in the quarter, and October's RYZUMVI presbyopia approval starts a new franchise line.

🩺 BD Closes Its First Pure Play Year Green

BD grew fiscal fourth quarter revenue 5.6% currency neutral, guided fiscal 2027 adjusted EPS to $13.10 to $13.30, and rose 2.1% against a 4.4% market decline. BDX

Full year revenue came in at $19.46 billion with adjusted earnings of $12.70 per diluted share, the first complete year since February's spin of the biosciences and diagnostics business into Waters. The policy line is the one to file: BD intends to invest $19 billion in the United States over several years, $3 billion of it in manufacturing, in exchange for relief from future Section 232 tariffs, subject to scope and milestones, and the year already carried a $66 million benefit from IEEPA tariff refunds. Interventional grew 7.6% in the quarter and Advanced Patient Monitoring 15%. Free cash flow rose 42.5% to $2.93 billion. An investor day follows on December 10.

🔬 The Liver Meeting Opens With a Second Line Answer

Gilead's Livdelzi normalized alkaline phosphatase in 75.4% of inadequately controlled PBC patients versus 16.1% on placebo in the Phase 3 IDEAL trial. GILD | AMLX | VIR

IDEAL enrolled 96 adults with primary biliary cholangitis whose alkaline phosphatase stayed above normal but below 1.67 times the upper limit despite a year of ursodeoxycholic acid, a population below the usual second line threshold. At week 52, 75.4% on Livdelzi reached the ALP normalization composite against 16.1% on placebo, response showed by one month, and serious adverse events were lower on drug than on placebo with none deemed related. Gilead says it is engaging with global regulators, and the paper is accepted at the Journal of Hepatology. The Liver Meeting runs through Monday in Denver.

Two more datasets frame the weekend. Amylyx confirmed its avexitide NDA remains on track for year end behind the LUCIDITY result it reported earlier this quarter, a 55% cut in Level 2 and Level 3 hypoglycemic events (p=0.000003), with the full data a late breaking oral at ObesityWeek on November 15 and $768.1 million of cash behind the launch plan. And Vir will present topline Phase 3 ECLIPSE 1 hepatitis delta data at the meeting with an investor call to follow; the numbers were not in Thursday's announcement, so that outcome is unknown as of this writing.

📋 Quick Hits

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review

This week a strategic bid appeared where public financing would not.

Reply if your answer is not on the list.